Combination phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathways

Journal of Carcinogenesis

Volumn 5, Issue , 2006, Pages

  Schniewind, Bodo ^a   Heintz, Kirsten ^a   Kurdow, Roland ^a   Ammerpohl, Ole ^a   Trauzold, Anna ^a   Emme, Doris ^a   Dohrmann, Peter ^a   Kalthoff, Holger ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYTOCHROME C; DEXAMETHASONE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DOXORUBICIN; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PHENYLBUTYRIC ACID; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; STRESS ACTIVATED PROTEIN KINASE; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CANCER SIZE; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME DEGRADATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN SECRETION; TREATMENT DURATION;

EID: 33845640064     PISSN: None     EISSN: 14773163     Source Type: Journal    
DOI: 10.1186/1477-3163-5-25     Document Type: Article

References (38)

1. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN, Pickle LW: Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005, 97(19):1407-1427.
2. Bilfinger TV: Surgical viewpoints for the definitive treatment of lung cancer. Respir Care Clin N Am 2003, 9(2):141-162.
3. Socinski MA, Morris DE, Masters GA, Lilenbaum R: Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003, 123(1 Suppl):226S-243S.
4. Ramnath N, Sommers E, Robinson L, Nwogu C, Sharma A, Cantor A, Bepler G: Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancer. Chest 2005, 128(5):3467-3474.
5. Dimitroulis J, Stathopoulos GP: Evolution of non-small cell lung cancer chemotherapy (Review). Oncol Rep 2005, 13(5):923-930.
6. Kumar A, Wakelee H: Second- and third-line treatments in non-small cell lung cancer. Curr Treat Options Oncol 2006, 7(1):37-49.
7. Gregoire V, Hittelman WN, Rosier JF, Milas L: Chemo-radiotherapy: radiosensitizing nucleoside analogues (review). Oncol Rep 1999, 6(5):949-957.
8. Kurdow R, Schniewind B, Zoefelt S, Boenicke L, Boehle AS, Dohrmann P, Kalthoff H: Apoptosis by gemcitabine in non-small cell lung cancer cell line KNS62 is induced downstream of caspase 8 and is profoundly blocked by Bcl-xL over-expression. Langenbecks Arch Surg 2005, 390(3):243-248.
9. Schniewind B, Christgen M, Kurdow R, Haye S, Kremer B, Kalthoff H, Ungefroren H: Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer 2004, 109(2):182-188.
10. Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S: Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 2001, 48 Suppl 1:S20-6.
11. Wagner S, Roemer K: Retinoblastoma protein is required for efficient colorectal carcinoma cell apoptosis by histone deacetylase inhibitors in the absence of p21Waf. Biochem Pharmacol 2005, 69(7):1059-1067.
12. Fronsdal K, Saatcioglu F: Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells. Prostate 2005, 62(3):299-306.
13. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Sklenar AR, Davis ME, Lucas DM, Fischer B, Shank R, Tejaswi SL, Binkley P, Wright J, Chan KK, Grever MR: A phase I and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005, 105(3):959-967.
14. Leone G, Voso MT, Teofili L, Lubbert M: Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin Immunol 2003, 109(1):89-102.
15. Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA: A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001, 7(8):2292-2300.
16. Samid D, Hudgins WR, Shack S, Liu L, Prasanna P, Myers CE: Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. Adv Exp Med Biol 1997, 400A:501-505.
17. Roh MS, Kim CW, Park BS, Kim GC, Jeong JH, Kwon HC, Suh DJ, Cho KH, Yee SB, Yoo YH: Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells. Apoptosis 2004, 9(5):583-589.
18. Zhang XD, Gillespie SK, Borrow JM, Hersey P: The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther 2004, 3(4):425-435.
19. Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, Paik DS, Czarnik AC, Payne SG, Spiegel S, Grant S: The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res 2004, 64(7):2590-2600.
20. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KA, Stein H, Mason DY: Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984, 32(2):219-229.
21. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991, 324(1):1-8.
22. Website title [http://facs.scripps.edu].
23. Boehle AS, Dohrmann P, Leuschner I, Kalthoff H, Henne-Bruns D: An improved orthotopic xenotransplant procedure for human lung cancer in SCID bg mice. Ann Thorac Surg 2000, 69(4):1010-1015.
24. Zhang X, Wei L, Yang Y, Yu Q: Sodium 4-phenylbutyrate induces apoptosis of human lung carcinoma cells through activating JNK pathway. J Cell Biochem 2004, 93(4):819-829.
25. Wang G, Reed E, Li QQ: Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncol Rep 2004, 12(5):955-965.
26. Kouraklis G, Theocharis S: Histone deacetylase inhibitors and anticancer therapy. Curr Med Chem Anti-Canc Agents 2002, 2(4):477-484.
27. Fujii T, Dracheva T, Player A, Chacko S, Clifford R, Strausberg RL, Buetow K, Azumi N, Travis WD, Jen J: A preliminary transcriptome map of non-small cell lung cancer. Cancer Res 2002, 62(12):3340-3346.
28. Lin HY, Chen CS, Lin SP, Weng JR, Chen CS: Targeting histone deacetylase in cancer therapy. Med Res Rev 2006.
29. Sowa Y, Sakai T: Butyrate as a model for "gene-regulating chemoprevention and chemotherapy.". Biofactors 2000, 12(1-4):283-287.
30. Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H, Gattermann N: The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006, 106(1):112-119.
31. Catley L, Tai YT, Chauhan D, Anderson KC: Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug Resist Updat 2005, 8(4):205-218.
32. Undevia SD, Kindler HL, Janisch L, Olson SC, Schilsky RL, Vogelzang NJ, Kimmel KA, Macek TA, Ratain MJ: A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol 2004, 15(11):1705-1711.
33. Singhal S, Amin KM, Kruklitis R, Marshall MB, Kucharczuk JC, DeLong P, Litzky LA, Kaiser LR, Albelda SM: Differentially expressed apoptotic genes in early stage lung adenocarcinoma predicted by expression profiling. Cancer Biol Ther 2003, 2(5):566-571.
34. McDoniels-Silvers AL, Stoner GD, Lubet RA, You M: Differential expression of critical cellular genes in human lung adenocarcinomas and squamous cell carcinomas in comparison to normal lung tissues. Neoplasia 2002, 4(2):141-150.
35. Fennell DA: Caspase regulation in non-small cell lung cancer and its potential for therapeutic exploitation. Clin Cancer Res 2005, 11(6):2097-2105.
36. Gallego MA, Joseph B, Hemstrom TH, Tamiji S, Mortier L, Kroemer G, Formstecher P, Zhivotovsky B, Marchetti P: Apoptosis-inducing factor determines the chemoresistance of non-small-cell lung carcinomas. Oncogene 2004, 23(37):6282-6291.
37. Cregan SP, Dawson VL, Slack RS: Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene 2004, 23(16):2785-2796.
38. Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA: Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 2001, 61(4):1477-1485.